Injectable Treatment Targets Deep Abdominal Fat in Early Clinical Results

An experimental injection called CBL-514 reduced visceral fat—the metabolically active fat surrounding internal organs—in early human trials, addressing fat that surgical procedures typically cannot remove. The drug works by selectively triggering cell death in fat tissue while leaving other cells unharmed, with participants receiving injections every three weeks showing an average 12% reduction in visceral fat volume within four weeks of final treatment. This approach could offer a non-surgical method to reduce visceral fat accumulation linked to metabolic disorders and cardiovascular disease.

CBL-514 works through a biological mechanism called apoptosis, causing fat cells to self-destruct while preserving surrounding tissues. The drug targets visceral fat specifically—deposits that accumulate around organs deep within the abdomen. Unlike cosmetic procedures such as liposuction or abdominoplasty, which only address surface-level fat, this injection reaches metabolically active fat that contributes to serious health conditions including insulin resistance, type 2 diabetes, and cardiovascular disease.

The clinical evidence comes from analysis of two phase 2 trials involving 40 participants with body mass indices between 22 and 30. Participants received injections into the lower abdomen at three-week intervals, with dose adjustments based on abdominal fat thickness. Safety monitoring showed only mild to moderate temporary reactions at injection sites, with no serious adverse events reported during the study period.